Let's say the results are good for these Omicron patients in this trial, and meet the short term study goals. What about the "long hauler" considerations though? Do (can) they stay on apabetalone? As participants during/after the study, for long term patient benefit and to also study the long haul benefits? Or is that something we will just have to learn about over time should apabetalone make it to market?

One of the reasons I am asking, is for potentially observing coincidental Diabetic Cardio/Renal patients, who were placed on apabetalone for a different reason - Covid.

I would "assume" that sicker patients would be somewhat more likely to enroll in these studies, and perhaps even want to stay on apabetalone due to their enhanced health risks, and potential long haul benefits related to Covid (and maybe also some "other" coincidental things/benefits)?

Could "acute" Covid and "long haul" Covid considerations become a previously unopened secret doorway to long term apabetalone that benefits the previously targeted "off label" groups as well, for which we received a BTD? While we wait officially for increased indications down the road with BoM2, PAH, etc?

Sorry, didn't take the time to review the study for details like long haul and staying on the medication as an option (for humanitarian reasons given safety profile). Just over thinking and spit-balling.